BORTEZOMIB | N206927 | DR REDDYS LABORATORIES LTD
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Larysa Sanchez | 17 | 2019-10-24 → 2026-05 | |
| Phase 3 | Active | Stichting European Myeloma Network | 709 | 2018-12-14 → 2029-11 | |
| Phase 3 | Active | Janssen Research & Development, LLC | 419 | 2020-06-12 → 2027-03-31 | |
| Phase 3 | Active | PETHEMA Foundation | 462 | 2018-10-22 → 2031-01 | |
| Phase 1/2 | Active | St. Jude Children's Research Hospital | 50 | 2016-01-29 → 2031-10 | |
| Phase 2 | Active | University of Arkansas | 160 | 2009-03 → 2027-12 | |
| Phase 3 | Active | National Cancer Institute (NCI) | 525 | 2008-07-28 → 2026-09-18 | |
| Phase 1 | Active | National Cancer Institute (NCI) | 24 | 2012-08-31 → 2027-03-03 | |
| Phase 3 | Active | Sanofi | 475 | 2017-12-07 → 2027-06-30 | |
| Phase 2 | Active | AbbVie | 156 | 2018-04-02 → 2031-05 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
21 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Mar 1, 2022 | SUPPL -2 | View Letter (PDF) |
| Oct 7, 2019 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.